picornavirus
pv
coronavirus
cov
positivestrand
rna
virus
infect
million
peopl
worldwid
year
result
wide
rang
clinic
outcom
report
studi
use
high
throughput
screen
small
molecul
identifi
sever
novel
inhibitor
sarscov
pro
ic
low
lm
interestingli
one
equal
inhibit
pro
pro
pv
cov
respect
use
comput
model
structur
featur
compound
individu
common
proteas
inhibitor
elucid
enhanc
knowledg
develop
antivir
agent
pv
cov
picornavirus
pv
small
nonenvelop
rna
virus
singl
strand
genom
rna
nucleotid
member
pv
includ
rhinovirus
rv
enterovirus
ev
coxsackievirus
cv
poliovirus
echovirus
encephalomyocard
virus
mening
viru
foot
mouth
virus
hepat
viru
among
rv
major
caus
common
cold
wherea
ev
cv
infect
caus
hand
foot
mouth
diseas
human
anim
sever
case
ev
damag
central
nervou
system
lead
viral
mening
enceph
sever
myocard
well
fatal
pulmonari
edema
cv
strain
b
major
human
pathogen
caus
mening
mycocard
lead
heart
failur
young
adult
congest
heart
failur
pv
chymotrypsinlik
proteas
name
pro
requir
process
polyprotein
matur
protein
viral
replic
repres
promis
antivir
drug
target
hand
coronavirus
cov
positivestrand
rna
virus
larger
genom
kb
typic
caus
respiratori
enter
diseas
pneumonia
exacerb
asthma
neurolog
symptom
myocard
human
domest
anim
outbreak
sever
acut
respiratori
syndrom
sar
caus
novel
human
cov
spread
china
countri
infect
total
peopl
kill
patient
sarscov
contain
proteas
pro
analog
pro
pv
respons
process
two
overlap
polyprotein
kda
kda
member
human
cov
includ
also
requir
pro
matur
viral
protein
sever
inhibitor
develop
inhibit
pro
rv
ev
pro
sarscov
howev
inhibitor
mutual
use
without
modif
exampl
potent
inhibitor
rv
picornavir
pro
fail
inhibit
sarscov
pro
unlik
pro
dimer
subunit
compos
three
domain
pro
monom
two
catalyt
domain
structurebas
sequenc
align
fig
show
sequenc
differ
may
alter
inhibitor
specif
studi
perform
high
throughput
screen
use
librari
compound
find
five
novel
inhibitor
sarscov
pro
also
inhibit
anoth
human
pro
inhibit
pro
one
compound
found
almost
equal
inhibit
pro
pro
comput
model
ration
bind
discrep
inhibitor
proteas
inform
use
develop
potent
individu
common
inhibitor
pro
pro
pv
cov
antivir
drug
discoveri
two
type
proteas
includ
pro
sarscov
pro
use
assay
inhibitor
studi
sarscov
pro
pro
prepar
report
previous
express
proteas
gene
clone
viral
cdna
use
polymeras
chain
reaction
pcr
report
elsewher
screen
lm
sar
pro
lm
fluorogen
substrat
dabcylktsavlqsgfrkmeedan
lm
approxim
compound
provid
korea
chemic
bank
daejeon
korea
use
enhanc
fluoresc
reaction
buffer
mm
bistri
ph
monitor
nm
excit
nm
use
fluoresc
plate
reader
compound
inhibit
proteas
activ
lm
select
next
assay
run
lm
five
hit
inhibit
sarscov
pro
lm
also
evalu
pro
pro
pro
pro
assay
solut
activ
proteas
lm
lm
fluorogen
substrat
buffer
mm
me
ph
optim
ph
proteas
respect
mm
hepe
ph
proteas
measur
presenc
fig
structurebas
sequenc
align
sarscov
pro
pro
pro
pro
pro
domain
accord
pro
shown
sequenc
secondari
element
accord
pro
structur
shown
arrow
indic
essenti
catalyt
amino
acid
cy
pro
pro
glu
pro
variou
concentr
inhibitor
obtain
ic
valu
model
analysi
use
crystal
structur
sar
pro
complex
peptid
inhibitor
pdb
code
structur
pro
pro
solv
us
structur
model
pro
construct
structur
rv
pro
pdb
code
dock
process
perform
use
autom
liganddock
subprogram
discoveri
studio
model
sbd
accelri
inc
san
diego
ca
set
paramet
chosen
control
precis
oper
genet
algorithm
dock
run
carri
use
standard
default
set
grid
resolut
site
open
bind
site
select
defin
activ
site
caviti
first
screen
librari
compound
inhibit
sarscov
pro
primari
screen
compound
show
inhibit
enzym
activ
lm
test
inhibitori
activ
lm
five
show
ic
valu
smaller
lm
accord
doserespons
curv
shown
fig
tabl
ic
valu
lm
respect
sar
pro
similar
inhibit
result
observ
pro
data
summar
tabl
pro
howev
inhibit
pro
pro
ic
valu
lm
lm
lm
respect
pro
pro
pro
pro
fig
summar
tabl
compound
contain
dihydropyrazol
ring
three
substitu
two
phenyl
group
lengthi
nbutylbenzimidazolylaminotoluen
sinc
inhibit
pro
pro
analogu
includ
obtain
anoth
compound
librari
evalu
shown
tabl
show
good
potenc
five
proteas
potent
compound
ic
valu
inhibit
l
proteas
measur
lm
sarscov
pro
lm
pro
lm
pro
lm
pro
lm
pro
tabl
compound
contain
four
ring
three
phenyl
group
one
imidazol
surround
central
dihydropyrazol
ring
without
lengthi
side
chain
seen
compound
benzylcyclohexan
ring
fuse
dihydropyrazol
ring
acetyl
iodobenzyl
group
attach
central
ring
show
less
inhibit
pro
pro
tabl
two
compound
shorter
side
chain
attach
benzimidazolyl
group
show
similar
inhibitori
activ
compar
tabl
inhibitor
competit
inhibitor
respect
substrat
data
shown
indic
bind
activ
site
ration
bind
discrep
inhibitor
proteas
bind
mode
sarscov
pro
four
proteas
model
shown
fig
first
four
inhibitor
sarscov
pro
rigid
thiazolopyridin
dichlorobenzoquinolinon
isoindoledion
oxazol
adopt
planar
structur
three
substitu
oxazol
ring
fix
conform
due
interact
acet
group
naryl
imino
group
well
biaryl
interact
phenyl
oxazol
prohibit
free
rotat
compound
consid
two
rigid
aromat
moieti
connect
small
linker
base
comput
model
aromat
moieti
bound
site
sar
proteas
form
hbond
hydrophob
interact
fig
shown
comput
model
side
chain
sar
pro
form
hbond
four
inhibitor
howev
correspond
amino
acid
residu
pro
lack
side
chain
form
hbond
compound
also
see
fig
lead
loss
inhibit
addit
pro
open
shallow
site
due
partial
blockag
pro
accord
crystal
structur
rv
pro
pro
lee
et
al
unpublish
result
compar
pro
also
see
fig
thu
pro
hold
compound
tightli
contrast
compound
flexibl
dihydropyrazol
planar
phenyl
group
link
sp
hybrid
carbon
dihydropyrazol
ring
free
rotat
differ
bind
mode
inhibitor
diphenyl
moieti
fit
well
site
sar
pro
fig
rest
molecul
site
beyond
bind
mode
compound
predict
also
bind
well
pro
consist
inhibit
data
fact
rv
pro
prefer
phenyl
group
site
evidenc
strong
inhibit
thu
could
ration
comput
model
among
five
hit
inhibit
three
pro
addit
pro
analogu
includ
bind
pro
pro
activ
site
similar
mode
data
shown
compar
minor
structur
differ
shorter
alkyl
group
attach
benzimidazol
ring
show
similar
inhibit
proteas
fuse
ring
system
phenyl
group
may
also
span
site
kind
proteas
yield
similar
inhibit
howev
show
significantli
better
inhibit
pro
appar
lengthi
side
chain
attach
phenyl
group
compound
provid
addit
interact
proteas
consist
bind
mode
shown
fig
howev
addit
interact
provid
pyridin
ring
bound
near
open
site
pro
best
inhibitor
identifi
far
pro
inhibit
pro
rv
also
cv
ev
howev
inhibit
pro
sarscov
may
partial
due
blockag
ring
rel
larger
side
chain
also
site
pro
narrow
although
deeper
therefor
chang
nonplanar
leucin
cyclohexan
without
chang
becam
good
inhibitor
sar
pro
unlik
ketomethyl
isoster
tripeptideconjug
ester
compound
peptidelik
random
screen
shown
studi
found
start
point
toward
develop
nonpeptid
multiplefunct
inhibitor
cov
pv
modif
individu
common
inhibitor
viral
proteas
hope
find
solut
possibl
reoccurr
sar
diseas
caus
virus
pro
pro
